Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 312

1.

First preclinical support for the 'danger theory' in inhibitor development.

van Vulpen LF, Mastbergen SC, Schutgens RE.

Haemophilia. 2016 Sep;22(5):654-6. doi: 10.1111/hae.13042. Epub 2016 Jul 25. No abstract available.

PMID:
27457662
2.

Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia.

Nijdam A, Foppen W, van der Schouw YT, Mauser-Bunschoten EP, Schutgens RE, Fischer K.

Haemophilia. 2016 Jul 11. doi: 10.1111/hae.12959. [Epub ahead of print]

PMID:
27396935
3.

Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.

Nijdam A, Foppen W, De Kleijn P, Mauser-Bunschoten EP, Roosendaal G, van Galen KP, Schutgens RE, van der Schouw YT, Fischer K.

Thromb Haemost. 2016 May 2;115(5):931-8. doi: 10.1160/TH15-08-0637. Epub 2016 Jan 21.

PMID:
26791021
4.

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.

van Galen KP, Engelen ET, Mauser-Bunschoten EP, van Es RJ, Schutgens RE.

Cochrane Database Syst Rev. 2015 Dec 24;(12):CD011385. doi: 10.1002/14651858.CD011385.pub2. Review.

PMID:
26704192
5.

How do patients and professionals differentiate between intra-articular joint bleeds and acute flare-ups of arthropathy in patients with haemophilia?

Timmer MA, Pisters MF, de Kleijn P, Veenhof C, Laros-van Gorkom BA, Kruip MJ, de Bie RA, Schutgens RE.

Haemophilia. 2016 May;22(3):368-73. doi: 10.1111/hae.12858. Epub 2015 Dec 3.

PMID:
26634961
6.

Facilitating the implementation of pharmacokinetic-guided dosing of prophylaxis in haemophilia care by discrete choice experiment.

Lock J, de Bekker-Grob EW, Urhan G, Peters M, Meijer K, Brons P, van der Meer FJ, Driessens MH, Collins PW, Fijnvandraat K, Leebeek FW, Cnossen MH; ‘OPTI-CLOT’ study group.

Haemophilia. 2016 Jan;22(1):e1-e10. doi: 10.1111/hae.12851. Epub 2015 Nov 27.

PMID:
26612493
7.

A patient with severe haemophilia A and multiple arterial thromboses caused by large vessel vasculitis: a case report.

Vos LM, Schutgens RE, de Valk HW, Spiering W, Bemelmans RH.

Haemophilia. 2016 Jan;22(1):e39-42. doi: 10.1111/hae.12787. Epub 2015 Nov 17. No abstract available.

PMID:
26572080
8.

Joint surgery in von Willebrand disease: a multicentre cross-sectional study.

van Galen KP, Meijer K, Vogely HC, Eikenboom J, Schutgens RE, Cnossen MH, Fijnvandraat K, van der Bom JG, Laros-van Gorkom BA, Leebeek FW, Mauser-Bunschoten EP; WiN study group.

Haemophilia. 2015 Nov 9. doi: 10.1111/hae.12834. [Epub ahead of print]

PMID:
26551280
9.

Core diameter of bone marrow aspiration devices influences cell density of bone marrow aspirate in patients with severe peripheral artery disease.

Teraa M, Schutgens RE, Sprengers RW, Slaper-Cortenbach I, Moll FL, Verhaar MC; Juventas Study Group.

Cytotherapy. 2015 Dec;17(12):1807-12. doi: 10.1016/j.jcyt.2015.08.004. Epub 2015 Sep 28.

PMID:
26428987
10.

Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.

van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel GJ, van Gelder IC, Schutgens RE, Klijn CJ; APACHE-AF Investigators.

Trials. 2015 Sep 4;16:393. doi: 10.1186/s13063-015-0898-4.

11.

Inhibitor development in non-severe haemophilia across Europe.

Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Hollingsworth R, Makris M; EUHASS Participants.

Thromb Haemost. 2015 Oct;114(4):670-5. doi: 10.1160/TH14-12-1044. Epub 2015 Aug 13. Erratum in: Thromb Haemost. 2016 Mar;115(3):684. Hollingsworth, R [Added].

PMID:
26293381
12.

IL-1β, in contrast to TNFα, is pivotal in blood-induced cartilage damage and is a potential target for therapy.

van Vulpen LF, Schutgens RE, Coeleveld K, Alsema EC, Roosendaal G, Mastbergen SC, Lafeber FP.

Blood. 2015 Nov 5;126(19):2239-46. doi: 10.1182/blood-2015-03-635524. Epub 2015 Aug 14.

PMID:
26276670
13.

FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies.

Fischer K, Iorio A, Hollingsworth R, Makris M; EUHASS collaborators.

Haemophilia. 2016 Jan;22(1):e36-8. doi: 10.1111/hae.12764. Epub 2015 Jul 24. No abstract available.

PMID:
26208036
14.

Silencing of protease-activated receptors attenuates synovitis and cartilage damage following a joint bleed in haemophilic mice.

Nieuwenhuizen L, Schutgens RE, Coeleveld K, Mastbergen SC, Schiffelers RM, Roosendaal G, Biesma DH, Lafeber FP.

Haemophilia. 2016 Jan;22(1):152-9. doi: 10.1111/hae.12770. Epub 2015 Jul 20.

PMID:
26189554
15.

The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.

Hazendonk HC, van Moort I, Fijnvandraat K, Kruip MJ, Laros-van Gorkom BA, van der Meer FJ, Meijer K, Peters M, Schutgens RE, Zwaan CM, Driessens MH, Polinder S, Leebeek FW, Mathôt RA, Cnossen MH.

Thromb Haemost. 2015 Aug 31;114(3):639-44. doi: 10.1160/TH14-11-0925. Epub 2015 Jun 11.

PMID:
26062822
16.

Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature.

Engelen ET, van Galen KP, Schutgens RE.

Haemophilia. 2015 Jul;21(4):419-29. doi: 10.1111/hae.12701. Epub 2015 Apr 30. Review.

PMID:
25929157
17.

The detrimental effects of iron on the joint: a comparison between haemochromatosis and haemophilia.

van Vulpen LF, Roosendaal G, van Asbeck BS, Mastbergen SC, Lafeber FP, Schutgens RE.

J Clin Pathol. 2015 Aug;68(8):592-600. doi: 10.1136/jclinpath-2015-202967. Epub 2015 Apr 20. Review.

PMID:
25897098
18.

Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study.

van Galen KP, Sanders YV, Vojinovic U, Eikenboom J, Cnossen MH, Schutgens RE, van der Bom JG, Fijnvandraat K, Laros-Van Gorkom BA, Meijer K, Leebeek FW, Mauser-Bunschoten EP; WiN Study Group.

Haemophilia. 2015 May;21(3):e185-92. doi: 10.1111/hae.12670. Epub 2015 Apr 9.

PMID:
25854528
19.

Differentiating between signs of intra-articular joint bleeding and chronic arthropathy in haemophilia: a narrative review of the literature.

Timmer MA, Pisters MF, de Kleijn P, de Bie RA, Fischer K, Schutgens RE.

Haemophilia. 2015 May;21(3):289-96. doi: 10.1111/hae.12667. Epub 2015 Apr 9. Review.

PMID:
25854291
20.

First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease.

Baaij M, van Galen KP, Urbanus RT, Nigten J, Eikenboom JH, Schutgens RE.

Br J Haematol. 2015 Nov;171(3):424-7. doi: 10.1111/bjh.13395. Epub 2015 Apr 7. No abstract available.

PMID:
25851809
Items per page

Supplemental Content

Loading ...
Write to the Help Desk